Amal M. Shoeib

Dr. Amal M. Shoeib


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2020 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
APAnna Pinson
Anna Pinson
AYAzure Yarbrough
Azure Yarbrough
JBJohn M. Bush
John M. Bush
CCChristian V. Cabanlong
Christian V. Cabanlong
ASAmal M. Shoeib
Amal M. Shoeib
ARAnna Radominska-Pandya
Anna Radominska-Pandya

Verified
Journal Article
Open access
PDF file
ASAmal M. Shoeib
Amal M. Shoeib
LBLance N. Benson
Lance N. Benson
Shengyu MuShengyu Mu
Shengyu Mu
LMLee Ann MacMillan-Crow
Lee Ann MacMillan-Crow
PPPaul L. Prather
Paul L. Prather
Cannabinoids exert anti-cancer actions; however, the underlying cytotoxic mechanisms and the cannabinoid receptors (CBRs) involved remain unclear. In this study, CBRs were characterized in several cancer cell lines. Radioligand binding screens surprisingly revealed specific binding only for the non-selective cannabinoid [3H]WIN-55,212-2, and not [3H]CP-55,940, indicating that the expressed CBRs exhibit atypical binding properties. Furthermore, [3H]WIN-55,212-2 bound to a single site in all cancer cells with high affinity and varying densities. CBR characteristics were next compared between human prostate cancer cell lines expressing low (PC-3) and high (DU-145) CBR density. Although mRNA for canonical CBRs was detected in both cell lines, only 5 out of 15 compounds with known high affinity for canonical CBRs displaced [3H]WIN-55,212-2 binding. Functional assays further established that CBRs in prostate cancer cells exhibit distinct signaling properties relative to canonical Gi/Go-coupled CBRs. Prostate cancer cells chronically exposed to both CBR agonists and antagonists/inverse agonists produced receptor downregulation, inconsistent with actions at canonical CBRs. Treatment of DU-145 cells with CBR ligands increased LDH-release, decreased ATP-dependent cell viability, and produced mitochondrial membrane potential depolarization. In summary, several cancer cell lines express CBRs with binding and signaling profiles dissimilar to canonical CBRs. Drugs selectively targeting these atypical CBRs might exhibit improved anti-cancer properties.

1 September 2018 in Experimental Cell Research
Verified
Journal Article
Closed access
CMChristopher L. Moore
Christopher L. Moore
ETErin M. Taylor
Erin M. Taylor
KBKelly K. Ball
Kelly K. Ball
LBLaura J. Bernock
Laura J. Bernock
RGRobert Griffin
Robert Griffin
MBMichael J. Borrelli
Michael J. Borrelli